NRIX (Nurix Therapeutics) Stock Based Compensation: $39.65 Mil (TTM As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NRIX Nurix Therapeutics Inc NRIX
61 GF Score
Price $25.22
GF Value $6.40
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Nurix Therapeutics Stock Based Compensation?

Nurix Therapeutics NRIX +0.36% 61 Stock Based Compensation is $39.65 Mil as of May. 2026. GuruFocus rates NRIX with a GF Score™ of 61/100 and a GF Value™ of $6.40 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Nurix Therapeutics's Stock Based Compensation for the three months ended in May. 2026 was $11.39 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in May. 2026 was $39.65 Mil.

Nurix Therapeutics Stock Based Compensation Related Terms

Nurix Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Nurix Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nurix Therapeutics Stock Based Compensation Chart

Nurix Therapeutics Annual Data
Trend Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Stock Based Compensation
Get a 7-Day Free Trial 15.80 28.13 33.67 33.93 37.97

Nurix Therapeutics Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.39 9.77 9.09 9.40 11.39
NRIX
61GF Score
Nurix Therapeutics Inc NRIX
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nurix Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $39.65 Mil.

What does a Stock Based Compensation of $39.65 Mil mean?
Nurix Therapeutics (NRIX) has a Stock Based Compensation of $39.65 Mil as of May. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Nurix Therapeutics and its competitors.
Is Nurix Therapeutics' Stock Based Compensation too high?
Nurix Therapeutics' current Stock Based Compensation is $39.65 Mil. Overall, Nurix Therapeutics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nurix Therapeutics' Stock Based Compensation compare to PHVS and NKTR?
Nurix Therapeutics' Stock Based Compensation of $39.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Nurix Therapeutics and its competitors. Nurix Therapeutics's current Stock Based Compensation is $39.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nurix Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nurix Therapeutics (NRIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.40, compared to a current price of $25.22 — trading 294.1% above its estimated fair value. The current Stock Based Compensation is $39.65 Mil. Nurix Therapeutics' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Nurix Therapeutics (NRIX), the current Stock Based Compensation is $39.65 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nurix Therapeutics (NRIX) Overvalued in 2026?

Based on GuruFocus' analysis, Nurix Therapeutics stock appears to be overvalued. The current stock price of $25.22 is trading 294.1% above its estimated GF Value™ of $6.40. GuruFocus considers Nurix Therapeutics to be Significantly Overvalued.

Key valuation signals for NRIX:

  • Stock Based Compensation: $39.65 Mil
  • GF Value™: $6.40 vs. price of $25.22 (294.1% above fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the NRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nurix Therapeutics Business Description

Address 1600 Sierra Point Parkway, Brisbane, CA, USA, 94005
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
61GF Score

Get the complete analysis for NRIX

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.22
Price
$6.40
GF Value